A New Way to Produce Hyperketonemia: Use of Ketone Ester in a Case of Alzheimer's Disease

Overview

Journal Alzheimers Dement

Specialties Neurology
Psychiatry

Date 2014 Oct 11

PMID 25301680

Citations 81

Authors

Mary T Newport

Theodore B VanItallie

Yoshihiro Kashiwaya

Michael Todd King

Richard L Veech

Affiliations

Soon will be listed here.

Abstract

Background: Providing ketone bodies to the brain can bypass metabolic blocks to glucose utilization and improve function in energy-starved neurons. For this, plasma ketones must be elevated well above the ≤ 0.2 mM default concentrations normally prevalent. Limitations of dietary methods currently used to produce therapeutic hyperketonemia have stimulated the search for better approaches.

Method: Described herein is a new way to produce therapeutic hyperketonemia, entailing prolonged oral administration of a potent ketogenic agent--ketone monoester (KME)--to a patient with Alzheimer's disease dementia and a pretreatment Mini-Mental State Examination score of 12.

Results: The patient improved markedly in mood, affect, self-care, and cognitive and daily activity performance. The KME was well tolerated throughout the 20-month treatment period. Cognitive performance tracked plasma β-hydroxybutyrate concentrations, with noticeable improvements in conversation and interaction at the higher levels, compared with predose levels.

Conclusion: KME-induced hyperketonemia is robust, convenient, and safe, and the ester can be taken as an oral supplement without changing the habitual diet.

Citing Articles

β-hydroxybutyrate is a metabolic regulator of proteostasis in the aged and Alzheimer disease brain.

Madhavan S, Diaz S, Peralta S, Nomura M, King C, Ceyhan K Cell Chem Biol. 2024; 32(1):174-191.e8.

PMID: 39626664 PMC: 11741930. DOI: 10.1016/j.chembiol.2024.11.001.

Ketogenic Diet: A Review of Composition Diversity, Mechanism of Action and Clinical Application.

Malinowska D, Zendzian-Piotrowska M J Nutr Metab. 2024; 2024:6666171.

PMID: 39463845 PMC: 11511599. DOI: 10.1155/2024/6666171.

Medium-Chain Triglycerides (MCTs) for the Symptomatic Treatment of Dementia-Related Diseases: A Systematic Review.

Meer N, Fischer T J Nutr Metab. 2024; 2024:9672969.

PMID: 38715705 PMC: 11074881. DOI: 10.1155/2024/9672969.

Effect of sodium-glucose cotransporter 2 inhibitors on serum low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus.

Imada T, Katakami N, Watanabe H, Nishina S, Sasaki S, Takahara M J Diabetes Investig. 2024; 15(7):843-850.

PMID: 38459768 PMC: 11215694. DOI: 10.1111/jdi.14179.

Ketosis prevents abdominal aortic aneurysm rupture through C-C chemokine receptor type 2 downregulation and enhanced extracellular matrix balance.

Sastriques-Dunlop S, Elizondo-Benedetto S, Arif B, Meade R, Zaghloul M, Luehmann H Sci Rep. 2024; 14(1):1438.

PMID: 38228786 PMC: 10791699. DOI: 10.1038/s41598-024-51996-7.

References

LECOCQ F, MCPHAUL Jr J . THE EFFECTS OF STARVATION, HIGH FAT DIETS, AND KETONE INFUSIONS ON URIC ACID BALANCE. Metabolism. 1965; 14:186-97. DOI: 10.1016/s0026-0495(65)80039-7. View

Clarke K, Tchabanenko K, Pawlosky R, Carter E, Knight N, Murray A . Oral 28-day and developmental toxicity studies of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate. Regul Toxicol Pharmacol. 2012; 63(2):196-208. PMC: 3809901. DOI: 10.1016/j.yrtph.2012.04.001. View

Kim Y, Lee F, Choi W, Lee S, Youn J . Insulin regulation of skeletal muscle PDK4 mRNA expression is impaired in acute insulin-resistant states. Diabetes. 2006; 55(8):2311-7. DOI: 10.2337/db05-1606. View

Kerndt P, Naughton J, Driscoll C, Loxterkamp D . Fasting: the history, pathophysiology and complications. West J Med. 1982; 137(5):379-99. PMC: 1274154. View

Vining E . Clinical efficacy of the ketogenic diet. Epilepsy Res. 1999; 37(3):181-90. DOI: 10.1016/s0920-1211(99)00070-4. View

Kashiwaya Y, Bergman C, Lee J, Wan R, King M, Mughal M . A ketone ester diet exhibits anxiolytic and cognition-sparing properties, and lessens amyloid and tau pathologies in a mouse model of Alzheimer's disease. Neurobiol Aging. 2013; 34(6):1530-9. PMC: 3619192. DOI: 10.1016/j.neurobiolaging.2012.11.023. View

Courchesne-Loyer A, Fortier M, Tremblay-Mercier J, Chouinard-Watkins R, Roy M, Nugent S . Stimulation of mild, sustained ketonemia by medium-chain triacylglycerols in healthy humans: estimated potential contribution to brain energy metabolism. Nutrition. 2013; 29(4):635-40. DOI: 10.1016/j.nut.2012.09.009. View

Clarke K, Tchabanenko K, Pawlosky R, Carter E, King M, Musa-Veloso K . Kinetics, safety and tolerability of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate in healthy adult subjects. Regul Toxicol Pharmacol. 2012; 63(3):401-8. PMC: 3810007. DOI: 10.1016/j.yrtph.2012.04.008. View

Owen O, Morgan A, Kemp H, Sullivan J, Herrera M, Cahill Jr G . Brain metabolism during fasting. J Clin Invest. 1967; 46(10):1589-95. PMC: 292907. DOI: 10.1172/JCI105650. View

10.

VanItallie T, Nufert T . Ketones: metabolism's ugly duckling. Nutr Rev. 2003; 61(10):327-41. DOI: 10.1301/nr.2003.oct.327-341. View

11.

Henderson S, Vogel J, Barr L, Garvin F, Jones J, Costantini L . Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr Metab (Lond). 2009; 6:31. PMC: 2731764. DOI: 10.1186/1743-7075-6-31. View

12.

de la Monte S . Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. Curr Alzheimer Res. 2012; 9(1):35-66. PMC: 3349985. DOI: 10.2174/156720512799015037. View

13.

Veech R, Chance B, Kashiwaya Y, LARDY H, Cahill Jr G . Ketone bodies, potential therapeutic uses. IUBMB Life. 2001; 51(4):241-7. DOI: 10.1080/152165401753311780. View

14.

Blomqvist G, Alvarsson M, Grill V, von Heijne G, Ingvar M, Thorell J . Effect of acute hyperketonemia on the cerebral uptake of ketone bodies in nondiabetic subjects and IDDM patients. Am J Physiol Endocrinol Metab. 2002; 283(1):E20-8. DOI: 10.1152/ajpendo.00294.2001. View

15.

Denton R, Randle P, BRIDGES B, Cooper R, Kerbey A, Pask H . Regulation of mammalian pyruvate dehydrogenase. Mol Cell Biochem. 1975; 9(1):27-53. DOI: 10.1007/BF01731731. View

16.

Talbot K, Wang H, Kazi H, Han L, Bakshi K, Stucky A . Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest. 2012; 122(4):1316-38. PMC: 3314463. DOI: 10.1172/JCI59903. View

17.

Cunnane S, Nugent S, Roy M, Courchesne-Loyer A, Croteau E, Tremblay S . Brain fuel metabolism, aging, and Alzheimer's disease. Nutrition. 2010; 27(1):3-20. PMC: 3478067. DOI: 10.1016/j.nut.2010.07.021. View

18.

Tate B, McKee T, Loureiro R, Dumin J, Xia W, Pojasek K . Modulation of gamma-secretase for the treatment of Alzheimer's disease. Int J Alzheimers Dis. 2013; 2012:210756. PMC: 3536039. DOI: 10.1155/2012/210756. View

19.

Veech R . The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism. Prostaglandins Leukot Essent Fatty Acids. 2004; 70(3):309-19. DOI: 10.1016/j.plefa.2003.09.007. View

20.

Krikorian R, Shidler M, DAngelo K, Couch S, Benoit S, Clegg D . Dietary ketosis enhances memory in mild cognitive impairment. Neurobiol Aging. 2010; 33(2):425.e19-27. PMC: 3116949. DOI: 10.1016/j.neurobiolaging.2010.10.006. View